Nektar Therapeutics said a California jury awarded it $90 million in damages in its breach-of-contract suit against Eli Lilly over the development of autoimmune drug rezpegaldesleukin. Lilly says it will seek to reverse the verdict.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
